Pfizer Biosimilars And Anti-Infectives Get Higher Profile Under New Structure
Pfizer will reorganize from two business units to three, creating a separate Consumer Healthcare unit alongside Innovative Medicines and Established Medicines. The changes will not be effective until the beginning of 2019.
You may also be interested in...
By setting up Pfizer Consumer Healthcare to have sales and earnings results reported separately, pharma giant could be making the division's assets more visible to potential buyers. Its sales pitch: "With a strong portfolio of global brands that span health and wellness, the company believes this business is well positioned to continue its growth."
The US launch of Pfizer's Inflectra has been an early case study for the US biosimilar market, and some biosimilar manufacturers and payers say market access challenges are worrying.
AstraZeneca is selling its late-stage small molecule antibiotics business to Pfizer in a deal that could reach more than $1.5bn, but the company – one of just a few big pharmas working in antibiotics R&D – says it will continue to study novel antibiotics via its MedImmune biologics division.